FDA Moves Toward New Peptide Compounding Policy

Agency submits proposed policy change for White House review as HHS signals support for expanded access to experimental peptides

Nearly three months after an FDA advisory committee recommended adding six experimental peptide groups to the agency’s Section 503A Bulks List, the Food and Drug Administration has taken a step toward revising its peptide-compounding policies.

FDA had not announced a decision on the committee’s July recommendations when, on October 15, it submitted a proposed policy change for White House review, according to Reuters. Five days later, HHS Secretary Robert F. Kennedy Jr. said the administration wants to establish a regulated market that would provide access to certain peptides through pharmacies operating under appropriate quality standards.

The developments suggest a potential shift in federal policy, but important questions remain. The proposed changes have not been publicly released, their relationship to the six peptides recommended by the advisory committee is unclear, and FDA has not announced a final decision on their inclusion on the Section 503A Bulks List.

An Unusual Advisory Committee Decision

During its July 23–24 meeting, FDA’s Pharmacy Compounding Advisory Committee (PCAC) considered seven peptide groups for possible inclusion on the Section 503A Bulks List. The committee recommended including six: BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon. It recommended against including Emideltide.

The recommendations were particularly noteworthy because FDA’s scientific reviewers had recommended against including all seven groups, citing insufficient clinical evidence, unresolved safety concerns, and challenges involving product quality and characterization. The committee’s recommendations are nonbinding. Inclusion on the 503A Bulks List would permit qualifying traditional compounders to use the listed bulk drug substances under applicable statutory conditions; it would not constitute FDA approval of the peptides as safe and effective drugs.

Safety Questions Remain

FDA continues to identify significant uncertainties involving several of the peptides considered in July. For BPC-157, the agency has raised concerns about potential immunogenicity, peptide-related impurities, and limitations in available human safety information.

For KPV, MOTS-c, and TB-500, FDA has reported an absence of identified human exposure data for the drug products and routes of administration evaluated. The agency has also identified safety and characterization concerns involving Semax and Epitalon.

These uncertainties are particularly relevant because compounded drugs are not subject to FDA’s premarket approval process for demonstrating safety, effectiveness, and quality.

A New Direction for Peptide Regulation?

The administration’s emerging approach appears intended to address the growing market for experimental peptides by providing a more controlled pathway for pharmacy compounding. Kennedy has argued that consumers are already obtaining peptides through sources that may lack appropriate quality oversight, and that regulated access could offer stronger safeguards.

However, important questions remain unanswered. The publicly available information does not establish which substances the proposed policy would cover, what conditions would apply to compounding, or how FDA would address the scientific concerns raised during its July review.

FDA has also continued enforcement against companies marketing unapproved peptide products. On September 1, the agency published warning letters to several peptide sellers, including Peak Performance Peptides, Royal Peptides, NuScience Peptides, Peptide Partners, and Tex Peptides.

Those enforcement actions involved products marketed as unapproved drugs and were separate from the advisory committee’s recommendations.

What Comes Next?

The October developments move the peptide-compounding discussion beyond the advisory committee’s recommendations and into active federal policy review.

For compounders, healthcare professionals, and regulatory specialists, the next important developments will be the publication of the proposed policy, clarification of the substances and compounding practices it would cover, and any subsequent FDA regulatory action.

The central regulatory challenge remains unchanged – how to improve oversight of an expanding peptide market without treating increased access as evidence that the products have been demonstrated to be safe and effective. 

Until FDA provides additional details, the scope and practical implications of the proposed changes remain uncertain.